Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q3 2021 · 10-Q
Revenue$155.97M$155.97M+254.2% vs Q3 2020 Net Income$49.80M$49.80M+50.9% vs Q3 2020 EPS Diluted$0.54$0.54+54.3% vs Q3 2020 Operating Income$50,974,000+57.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$42,680,000N/M Margins · derivedOperating margin32.7%−40.7 pt vs Q3 2020
Net margin31.9%−43.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 9, 2021 · 40 d after period end